Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy

Gail D. Sckisel, Annie Mirsoian, Myriam N. Bouchlaka, Julia K. Tietze, Mingyi Chen, Bruce R. Blazar, William J. Murphy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αCD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of negative regulators such as cytotoxic T lymphocyte antigen-4 (CTLA-4) could simultaneously prolong CD8+ T cell responses and augment T cell anti-tumor effects. We devised a regimen in which anti-CTLA-4 was administered late so as to delay contraction and minimize toxicities. This late administration both enhanced and prolonged CD8 T cell activation without the need for additional IL-2. The quality of the T cell response was improved with increased frequency of effector/effector memory phenotype cells along with improved lytic ability and bystander expansion. This enhanced CD8 response translated to improved anti-tumor responses both at the primary and metastatic sites. Importantly, toxicities were not exacerbated with combination. This study provides a platform for rational design of immunotherapy combinations to maximize anti-tumor immunity while minimizing toxicities.

Original languageEnglish (US)
Pages (from-to)1541-1552
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume64
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

CTLA-4 Antigen
Immunotherapy
T-Lymphocytes
Neoplasms
Interleukin-2
Aptitude
Immunity
Phenotype

Keywords

  • Anti-CTLA-4
  • Bystander activation
  • Checkpoint blockade
  • Immunotherapy
  • Toxicities

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. / Sckisel, Gail D.; Mirsoian, Annie; Bouchlaka, Myriam N.; Tietze, Julia K.; Chen, Mingyi; Blazar, Bruce R.; Murphy, William J.

In: Cancer Immunology, Immunotherapy, Vol. 64, No. 12, 01.12.2015, p. 1541-1552.

Research output: Contribution to journalArticle

Sckisel, Gail D. ; Mirsoian, Annie ; Bouchlaka, Myriam N. ; Tietze, Julia K. ; Chen, Mingyi ; Blazar, Bruce R. ; Murphy, William J. / Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. In: Cancer Immunology, Immunotherapy. 2015 ; Vol. 64, No. 12. pp. 1541-1552.
@article{e6cd482fd67148e2b1c6035e84747879,
title = "Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy",
abstract = "We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αCD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of negative regulators such as cytotoxic T lymphocyte antigen-4 (CTLA-4) could simultaneously prolong CD8+ T cell responses and augment T cell anti-tumor effects. We devised a regimen in which anti-CTLA-4 was administered late so as to delay contraction and minimize toxicities. This late administration both enhanced and prolonged CD8 T cell activation without the need for additional IL-2. The quality of the T cell response was improved with increased frequency of effector/effector memory phenotype cells along with improved lytic ability and bystander expansion. This enhanced CD8 response translated to improved anti-tumor responses both at the primary and metastatic sites. Importantly, toxicities were not exacerbated with combination. This study provides a platform for rational design of immunotherapy combinations to maximize anti-tumor immunity while minimizing toxicities.",
keywords = "Anti-CTLA-4, Bystander activation, Checkpoint blockade, Immunotherapy, Toxicities",
author = "Sckisel, {Gail D.} and Annie Mirsoian and Bouchlaka, {Myriam N.} and Tietze, {Julia K.} and Mingyi Chen and Blazar, {Bruce R.} and Murphy, {William J.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s00262-015-1759-4",
language = "English (US)",
volume = "64",
pages = "1541--1552",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "12",

}

TY - JOUR

T1 - Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy

AU - Sckisel, Gail D.

AU - Mirsoian, Annie

AU - Bouchlaka, Myriam N.

AU - Tietze, Julia K.

AU - Chen, Mingyi

AU - Blazar, Bruce R.

AU - Murphy, William J.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αCD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of negative regulators such as cytotoxic T lymphocyte antigen-4 (CTLA-4) could simultaneously prolong CD8+ T cell responses and augment T cell anti-tumor effects. We devised a regimen in which anti-CTLA-4 was administered late so as to delay contraction and minimize toxicities. This late administration both enhanced and prolonged CD8 T cell activation without the need for additional IL-2. The quality of the T cell response was improved with increased frequency of effector/effector memory phenotype cells along with improved lytic ability and bystander expansion. This enhanced CD8 response translated to improved anti-tumor responses both at the primary and metastatic sites. Importantly, toxicities were not exacerbated with combination. This study provides a platform for rational design of immunotherapy combinations to maximize anti-tumor immunity while minimizing toxicities.

AB - We have demonstrated that immunostimulatory therapies such as interleukin-2 (IL-2) and anti-CD40 (αCD40) can be combined to deliver synergistic anti-tumor effects. While this strategy has shown success, efficacy varies depending on a number of factors including tumor type and severe toxicities can be seen. We sought to determine whether blockade of negative regulators such as cytotoxic T lymphocyte antigen-4 (CTLA-4) could simultaneously prolong CD8+ T cell responses and augment T cell anti-tumor effects. We devised a regimen in which anti-CTLA-4 was administered late so as to delay contraction and minimize toxicities. This late administration both enhanced and prolonged CD8 T cell activation without the need for additional IL-2. The quality of the T cell response was improved with increased frequency of effector/effector memory phenotype cells along with improved lytic ability and bystander expansion. This enhanced CD8 response translated to improved anti-tumor responses both at the primary and metastatic sites. Importantly, toxicities were not exacerbated with combination. This study provides a platform for rational design of immunotherapy combinations to maximize anti-tumor immunity while minimizing toxicities.

KW - Anti-CTLA-4

KW - Bystander activation

KW - Checkpoint blockade

KW - Immunotherapy

KW - Toxicities

UR - http://www.scopus.com/inward/record.url?scp=84947038990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947038990&partnerID=8YFLogxK

U2 - 10.1007/s00262-015-1759-4

DO - 10.1007/s00262-015-1759-4

M3 - Article

VL - 64

SP - 1541

EP - 1552

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 12

ER -